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Abstract: Sirt1 is a NAD+-dependent protein-modifying enzyme involved in regulating gene
expression, DNA damage repair, metabolism and survival, as well as acts as an important
subcellular target of resveratrol. The complex mechanisms underlying Sirt1 signaling during
carcinogenesis remain controversial, as it can serve both as a tumor promoter and suppressor.
Whether resveratrol-mediated chemopreventive effects are mediated via Sirt1 in CRC growth
and metastasis remains unclear; which was the subject of this study. We found that resveratrol
suppressed proliferation and invasion of two different human CRC cells in a dose-dependent
manner, and interestingly, this was accompanied with a significant decrease in Ki-67 expression. By
transient transfection of CRC cells with Sirt1-ASO, we demonstrated that the anti-tumor effects of
resveratrol on cells was abolished, suggesting the essential role of this enzyme in the resveratrol
signaling pathway. Moreover, resveratrol downregulated nuclear localization of NF-κB, NF-κB
phosphorylation and its acetylation, causing attenuation of NF-κB-regulated gene products (MMP-9,
CXCR4) involved in tumor-invasion and metastasis. Finally, Sirt1 was found to interact directly with
NF-κB, and resveratrol did not suppress Sirt1-ASO-induced NF-κB phosphorylation, acetylation
and NF-κB-regulated gene products. Overall, our results demonstrate that resveratrol can suppress
tumorigenesis, at least in part by targeting Sirt1 and suppression of NF-κB activation.
Keywords: human colon cancer; Sirt1; NF-κB; alginate; resveratrol; carcinogenesis
1. Introduction
Colorectal cancer (CRC) is one of the major leading causes of tumor-associated deaths in the
world, with high rates of incidence and disease-related mortality and morbidity [1]. The pathogenesis
and development of CRC is a multi-step process that is orchestrated through complex molecular
signaling mechanisms, including the mutations in multiple genes, such as proto-oncogenes and tumor
suppressor genes [2].
There is a growing recognition that the tumor microenvironment is very complex and contains
different cell types and factors, which play a critical role during the initiation, proliferation, metastasis
and maintenance of cancers [3–6]. Moreover, several lines of evidence have shown that the
transcription factor, nuclear factor-kappa B (NF-κB), is a critical determinant, as it regulates a
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variety of pathophysiological processes, such as inflammation, cell survival, proliferation, invasion,
apoptosis, differentiation and chemoresistance in different tumor cells, including CRC [7,8]. Therefore,
pharmacologically-safe anti-tumor agents with the potential to influence the tumor microenvironment
and inhibit NF-κB signaling activation may enhance chemosensitivity and reduce metastasis of tumor
cells and provide a promising approach for the prevention or treatment of tumors.
Resveratrol (3,5,41-trihydroxystilbene), a naturally-occurring polyphenolic and multi-targeted
component that belongs to the class of stilbenes present in more than 70 plant species, including skin
of red grapes, berries and peanuts [9–11], has been shown to act as a specific inhibitor of NF-κB in
different tumor cells [12,13]. Several lines of evidence have shown the anti-oxidant, anti-inflammatory
and neuroprotective properties of resveratrol [14], leading to its cancer chemopreventive and
chemotherapeutic activity in various cancer cell lines [9]. Several reports have shown that resveratrol
has inhibitory effects on various types of cancer cell lines and preclinical animal models of various
cancers, such as colon, breast and lymphoma, through its activity on diverse subcellular targets,
including Sirt1 [15–21]. Sirtuins (SIRT1 to SIRT7), the class III histone/protein deacetylases (HDACs),
have been shown to regulate a variety of cellular processes involved in metabolism, differentiation,
inflammation, aging, apoptosis, proliferation and cell cycle regulation. The best identified and
characterized among the human sirtuins is sirtuin1 (silent information regulator-1, SIRT1), a nuclear
enzyme, that has been shown to regulate important metabolic and physiological processes that
play a critical role in processes related to cancer [22–26]. Furthermore, it has been reported that
acetylation and deacetylation of proteins is a hallmark of the epigenetic gene expression modulation in
tumorigenesis [27–30]. This enzymatic protein modulation is also post-translationally very important
for the regulation of the function of many different proteins [31,32]. Resveratrol is a specific and potent
activator of subcellular target histone deacetylase Sirt1 in different human tissues, including human
tumors [17,33–36].
There is still poor understanding of whether Sirt1 acts as a tumor promoter through induction
of genomic instability in cancers [37–41], possibly through deacetylation and suppression of p53
activity [42,43], and/or modulating the activity of various tumor suppressing proteins in different
cancer types, including colon cancer. Furthermore, Sirt1 may act as a tumor suppressor through
improving genetic stability, as shown in in vivo normal tissue cells, and in addition to that, Sirt1
regulates other signaling mechanisms. Indeed, it has been reported that Sirt1 blocks NF-κB signaling
pathway activation, which induces inflammation and tumor invasion [42–48]. Furthermore, the
hallmarks of tumor are the genetic instability of tumor cells, whereas healthy cells with intact
innate signaling pathways are able to antagonize cancer-promoting signals and are able to resolve
any cancer-promoting signals [49]. Apparently some genes, including sirtuins, may function in a
context-dependent manner, including conditions, such as tumor microenvironment, divergent cellular
p53 status and origin of the tumor, to exert tumor-promoting or -suppressing qualities [49].
We hypothesize that transcriptional modulation of Sirt1 regulates one of the key mechanisms of the
resveratrol-mediated anti-tumorigenic effects in CRC cells. To examine this hypothesis, we evaluated
an in vitro 3D-model culture of carcinogenesis to study the effects of resveratrol targeting Sirt1 with
specific antisense oligonucleotides (ASO) on cellular proliferation, invasion and NF-κB signaling
pathways in human CRC cells.
2. Experimental Section
2.1. Antibodies
Polyclonal antibodies against Sirt1 and CXCR4 were purchased from Abcam PLC (Cambridge,
UK). Anti-phospho-specific p65 (NF-κB) and anti-phospho-specific p50 (NFκB) were obtained from Cell
Technology (Beverly, MA, USA). Anti-MMP-9 was purchased from R&D Systems, Inc., (Heidelberg,
Germany). Anti-Ki-67 and secondary antibodies used for fluorescence labelling were purchased from
Dianova (Hamburg, Germany). Monoclonal poly(ADP-ribose) polymerase (PARP) antibodies were
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purchased from Becton Dickinson (Heidelberg, Germany). Acetylated lysine (Ac-K-103) antibody was
purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against β-actin and Ki-67
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Alkaline phosphatase-linked
sheep anti-mouse and sheep anti-rabbit secondary antibodies for immunoblotting were purchased
from EMD Millipore (Schwalbach, Germany).
2.2. Growth Media, Chemicals and Cytokines
Cell culture growth medium consisting of Dulbecco’s Modified Eagle’s Medium/Ham’s F-12
(1:1), 10% fetal bovine serum (FBS), 0.5% amphotericin B solution, 1% penicillin streptomycin solution
(10,000 IU/10,000 IU), 75 µg/mL ascorbic acid, 1% essential amino acids and 1% glutamine was
obtained from Seromed (Munich, Germany). Epon was obtained from Plano (Marburg, Germany).
Alginate was purchased from Sigma (Munich, Germany). Resveratrol with purity greater than 98%
was purchased from Sigma. A 100 mM stock solution of resveratrol (molecular weight 228.2) was
prepared in ethanol and further diluted in cell culture medium to prepare working concentrations.
The maximum final content of ethanol in cultures was less than 0.1%. This concentration was also used
as a control.
2.3. Cell Lines and Cell Culture
Human HCT116 CRC cells were obtained from the European Collection of Cell Cultures (Salisbury,
UK). SW480 CRC cells were purchased from the American Type Culture Collection (ATCC, Manassas,
VA, USA). The cells were maintained in tissue culture flasks in growth medium and in a humidified
incubator at 37 ˝C in an atmosphere of 95% air and 5% CO2. The medium was changed every three
days, and cells were passaged using trypsin/EDTA.
2.4. Alginate Culture and Experimental Design
A detailed description of the cell cultivation in alginate is given by Shakibaei and de Souza [50–52].
Briefly, the pellet of HCT116 and SW480 cells (1 ˆ 106/mL) was resuspended in sterile alginate medium
(2% in 0.15 M NaCl, stirring for 1–2 h) and slowly added dropwise into a solution containing 100 mM
CaCl2 at ambient temperature (AT). The alginate beads polymerized in the presence of CaCl2 after
10 min. Subsequently, the CaCl2 solution was removed and the alginate beads washed three times
with 0.15 M NaCl solution and twice with serum-starved medium (3% FBS) before starting treatment.
2.5. Antisense and Lipofectin-Mediated Transfection
Transient transfection of HCT116 and SW480 cells in alginate beads was performed as
described previously [53]. Phosphorothioated antisense oligonucleotide derived from the mRNA
nucleotide sequence of sirtuin-1 gene (Sirt1-ASO; sequence 51-GTATTCCACATGAAACAGACA-31)
and control sense oligonucleotides (Sirt1-SO; sequence 51-TGTCTGTTTCATGTGGAATAC-31) used in
the experiments were synthesized by Eurofins (MWG/Operon, Ebersberg, Germany). Sirt1-ASO and
Sirt1-SO were phosphorothioate-modified to protect them from the cell nucleases. Alginate beads of
HCT116 and SW480 cells (1 ˆ 106/mL) were either left untreated or treated with 5 µM resveratrol, or
transfected by incubation with 0.5 µM Sirt1-ASO or Sirt1-SO and 10 µL/mL Lipofectin transfection
reagent (Invitrogen), or treated with various concentrations of resveratrol (1, 5, 10 µM) and co-treated
with 0.5 µM Sirt1-ASO, or Sirt1-SO and 10 µL/mL Lipofectin transfection reagent in serum-starved
medium (3% FCS) for 14 days. These experiments were performed in triplicate, and the results are
provided as mean values from three independent experiments.
2.6. Cell Proliferation and Viability Assay
HCT116 and SW480 cell lines (1 ˆ 106/mL) were cultured in alginate beads in Petri dishes, treated
with or without different concentrations of individual resveratrol (1, 5, 10, 20 and 50 µM) to get the IC50
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value drugs as described previously from our group [52]. In a separate set of experiment, CRC cells
were treated with different concentrations of resveratrol (1, 5, 10 µM) or co-treated with fixed (0.5 µM)
Sirt1-ASO or Sirt1-SO, 10 µL/mL Lipofectin transfection reagent and with different concentrations
of resveratrol (1, 5, 10 µM) in serum-starved medium for 21 days. To examine the cell viability and
proliferation of colorectal cancer cells in alginate bead culture, cells were retrieved from alginate
and measured using the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide).
To release the CRC cells from the alginate, alginate beads were washed two times with PBS and
dissolved in 55 mM sodium citrate solution. To remove excess alginate, cells were centrifuged, washed
twice with sterile PBS and resuspended in 2 mL modified cell culture medium (DMEM without phenol
red, without ascorbic acid and only 3% FBS). Subsequently, 100 µL of cell suspension was distributed
to a 96-well-plate; to each well were immediately added 10 µL MTT solution (5 mg/mL), and the
plate was incubated for 4 h at 37 ˝C. Finally, 100 µL of the MTT solubilization solution (10% Triton
x-100/acidic isopropanol) was added per well and the cells incubated overnight at 37 ˝C. Absorbance
was measured at 550 nm (OD550) using a revelation 96-well multi-scanner plate reader (Bio-Rad
Laboratories Inc., Munich, Germany). The results obtained were calculated and were represented
by survival relative to controls. This experiment was repeated 3 times independently, and statistical
analysis was done to obtain the final values.
2.7. Cell Invasion and Migration Assay
The cell invasion and migration ability of 2 different colorectal cell lines was evaluated using
alginate beads as described previously [52]. For the invasion assay, 1 ˆ 106/mL of each type
of cell were cultured in alginate beads in Petri dishes, treated with different concentrations of
resveratrol (1, 5, 10 µM) or co-treated with fixed (0.5 µM) Sirt1-ASO or Sirt1-SO, 10 µL/mL Lipofectin
transfection reagent and with different concentrations of resveratrol (1, 5, 10 µM) in serum-starved
medium for 14 days. After incubation for 14 days, noninvasive cells and alginate beads were removed
from the Petri dishes, and migrated cells adhering and forming colonies on the bottom of the Petri
dish were fixed with methanol for 10 min, stained with toluidine blue for 5 min, carefully washed two
times with PBS and photographed under the light microscope (Zeiss, Jena, Germany). The number
of migrated and positively-stained adherent colonies were quantified and evaluated manually by
counting all colonies.
2.8. Electron Microscopy
The alginate cultures were fixed for 1 h in Karnovsky’s fixative followed by post-fixation in a 1%
OsO4 solution in phosphate buffer, as previously described [50]. After rinsing and dehydration in
ascending alcohol series, the samples were embedded in Epon and ultrathin sections prepared with a
Reichert-Jung Ultracut E (Darmstadt, Germany). Ultrathin sections were contrasted with 2% uranyl
acetate/lead citrate and examined under a Zeiss transmission electron microscope, Jena, Germany
(TEM 10, Institute of Pharmacology, Berlin, Germany), or Jeol 1200 EXII, Akishima Tokyo, Japan
(Department of Anatomy and Cell Biology, Martinsried, Germany).
2.9. Western Blot Analysis
For Western blot analysis, proteins were extracted from the alginate cultures with lysis buffer
(50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM
sodium pyrophosphate, 100 mM sodium fluoride, 0.01% (v/v) aprotinin, 4 µg/mL of pepstatin A,
10 µg/mL of leupeptin, 1 mM phenylmethylsulfonyl fluoride, PMSF) on ice for 30 min, as previously
described [54,55]. Total protein concentration was measured with the bicinchonic acid assay system
(Uptima, Monlucon, France) using bovine serum albumin as a standard. Samples were further reduced
with 2-mercaptoethanol and equal quantities of protein (500 ng/lane), separated under reducing
conditions by SDS-PAGE and transferred onto nitrocellulose membranes using a trans-blot apparatus
(Bio-Rad). After preincubation in blocking buffer (5% skimmed milk powder in PBS, 0.1% Tween 20)
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for 2 h, membranes were incubated with primary antibodies at 4 ˝C overnight, washed three times
with blocking buffer and then further incubated with alkaline phosphatase-conjugated secondary
antibodies for 1.5 h at ambient temperature. After further washing in 0.1 M Tris, pH 9.5, containing
0.05 M MgCl2 and 0.1 M NaCl, specific antigen-antibody complexes were detected using nitro blue
tetrazolium and 5-bromo-4-chloro-3-indoylphosphate (p-toluidine salt; Pierce).
2.10. Isolation of CRC Cell Nuclear Extracts
Cell nuclear extracts were isolated as previously described [56]. Briefly, cells were trypsinized
and washed twice in 1 mL of ice-cold PBS. The supernatant was carefully removed. The cell pellet
was resuspended in hypotonic lysis buffer containing protease inhibitors and was incubated on ice
for 15 min. Then, 12.5 µL of 10% Nonidet P-40 was added, and the cell suspension was vigorously
mixed for 15 s. The extracts were centrifuged for 1.5 min. The supernatants (cytoplasmic extracts) were
frozen at ´70 ˝C. Twenty five microliters of ice-cold nuclear extraction buffer were added to the pellets
and incubated for 30 min with intermittent mixing. Extracts were centrifuged, and the supernatant
(nuclear extracts) was transferred to pre-chilled tubes for storage at ´70 ˝C.
2.11. Immunofluorescence Microscopy Analysis of Monolayer Cultures
HCT116 and SW480 cells were cultured on glass plates in a monolayer. After fixation with
methanol, cells were rinsed with PBS and incubated with bovine serum albumin (BSA) for 30 min.
Primary antibodies were diluted 1:50 in PBS/BSA, incubated overnight at 4 ˝C in a humid chamber,
washed three times with PBS/BSA followed by incubation with rhodamine-coupled secondary
antibodies for 1.5 h and finally washed again three times with aqua dest. Counter staining
was performed with DAPI (49,6-diamidino-2-phenylindole, Sigma) to visualize cell nuclei. Slides
were covered with fluoromount mountant and examined under a fluorescent microscope (Leica,
Darmstadt, Germany).
2.12. Statistical Analysis
Each experiment was performed three times individually with three replicates. Data were
expressed as the mean values (˘SD) or SEM, as indicated in the figures. Results were analyzed by
an unpaired Student’s t-test and by one-way ANOVA followed by a post hoc test to compare the
parameters of each group. Differences were considered to be statistically significant for p < 0.05.
3. Results
The purpose of this paper was to investigate whether resveratrol/Sirt1-mediated signaling during
carcinogenesis plays a role against the growth and metastasis of CRC cells. We used two different
well-characterized cell lines, microsatellite instability MSI+ (HCT116) and MSI´ (SW480) cells, as well
as cells that are WT for p53 (HCT116) and mutant (SW480) [57], since 5-Fluorouracil (5FU)-mediated
resistance is tightly linked to MSI and p53 status in CRC, derived from colorectal cancer cells, and we
evaluated the effects of resveratrol on Sirt1 targeting using Sirt1-ASO on NF-κB signaling pathways in
human CRC cells.
3.1. Resveratrol Upregulated the Expression of Sirt-1 Protein in CRC Cells in Vitro
First, we examined whether resveratrol stimulates the expression of Sirt1 in different CRC cells.
HCT116 and SW480 cells in alginate culture were either left untreated or treated with different
concentrations of resveratrol (1, 2, 3, 5, 10 µM) for 14 days. Whole cell lysates were fractionated and
analyzed by immunoblotting using anti-Sirt1 antibodies. As shown in Figure 1, Western blotting
and densitometric analysis were performed in triplicate, and treatment with resveratrol alone clearly
upregulated the expression of Sirt1 protein in a dose-dependent manner in both CRC cells (HCT116
and SW480).
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Figure 1. The effects of resveratrol on Sirt1 expression in CRC cells in the alginate tumor
micro nvironment. Serum-starved HCT116 and SW480 cell li es in alginat culture (1 ˆ 106/mL) were
either left untreated or treated with different concentrations of resveratrol alone (1, 2, 3, 5, 10 µM) for
14 days. Whole cell lysat s were prepar d and analyzed by Western blotting with antibodies against
Sirt1. Sirt1 c ntrol peptide (Co Pep) was use s control for Sirt1 antibody specificity. The results
shown are representative of thre independent experiments. Housekeeping protein β-actin s rved
as a loading control in all experiments. Densi omet c valuation of protein expression as r vealed
by Western blot analysis was p rform d n tripl ate. Values we e compared to the control and
statistically-significant values with p < 0.05. Significant values are marked with an as erisk (*).
3.2. Inhibitory Effects of Resveratrol on Cellular Proliferation and Viability of CRC Cells Were Abolished by
Knockdown of Sirt1
HCT116 and SW480 cells in alginate beads (1 ˆ 106/mL) were either left untreated or treated
with different concentration of resveratrol (0, , 5, 10 µM), t ansfected with Sirt1-SO, Sirt1-ASO
(0.5 µM) in the presence of Lipof ctin (10 µL/mL) or cells were o-treated wi h different concentrations
of resve atrol (1, 5, 10 µM) and with Sirt1-SO, Sirt1-ASO (0.5 µM) in the presence of Lipofectin
(10 µL/mL) for 21 days in serum-deprived medium, and cell viability was measured us ng the MTT
assay, as described i the Experimental S ction. The tumor ce ls proliferated continuously in control
lginate cultures, whereas esveratrol inhibited the proliferation and increased cell death in HCT116
nd SW480 cells in a dose-dep ndent manner (Figure 2A,B). Tre tme t of CRC cells with different
concentrations of resveratrol and Sir 1-SO (0.5 µM) in the pres nce of Lipofectin induced growth
inhibito y effects on c llular viability similar to resveratrol alone or Sirt1-SO (0.5 µM) alone (not
shown). In contrast, knockdown of Sirt1 w th ASO abolished the inhibitory effects of resveratrol on
cell viability and proliferati n similar o CRC cells transfected w th Sirt1-ASO (0.5 µM) alone (n t
shown). Furthermo e, to examine, whe her kno kdown o Sirt1 protein levels with specific ASO are
till low 21 days after transfect on during tumorigenesis in alginate cultures, we performed Western
blot analysis. HCT116 (Figure 2C) and SW480 (not shown) ce ls in alginate beads (1 ˆ 106/mL) i her
served s controls or were t ated s escribed above (Figure 2). The coll ct d cells were subj cted
to immunolabeling with Si t1 antibo y. As demonstrated in West rn blot analysis, t atment with
resveratrol and Sirt1-SO upregulated the expression of S rt1 protei in a time-dependent manner
(Figure 2C) in both CRC cells. In contrast, treatment with irt1-ASO clearly downr gulat d levels of
Sirt1 protein in a time-depende t manner in both CRC cells (Figure 2B), and it ke ps 21 ays after
transfection in alginat cultures (Figure 2C). Taken together, these findings suggest an essential role fo
Sirt1 in resveratrol-promoting anti-tumorigenic effects in CRC c lls.
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effects  of  resveratrol  against  CRC  migration  and  invasion  in  the  3D  alginate‐based  culture 
microenvironment, by evaluating through toluidine blue staining. As shown in Figure 3, treatment 
of the cells with resveratrol alone inhibited migration of HCT116 (Figure 3A,B) and SW480 (Figure 
3A,C)  cells  through  the  alginate‐based matrix  in  a dose‐dependent manner.  Interestingly,  it was 
noted that there was no effect of Sirt1‐SO on resveratrol‐mediated migration inhibition on CRC cells. 
However,  knockdown  of  Sirt1  with  ASO  blocked  resveratrol‐inhibited  migration  effects  and 
significantly increased the number of migrated cells (Figure 3A–C). 
Figure 2. Effects of resveratrol and Sirt1-ASO on the proliferation of CRC cells in alginate culture.
Serum-starv d HCT116 (A) and SW480 (B) cell lines in alg nate culture (1 ˆ 106/mL) were either l ft
untreated, or treated with different concentrations of resveratrol alone (1, 5, 10 µM), or transf cted with
0.5 µM sense oligonucleotide (SO) trol, or a tisense oligonucle tides (ASO) against Sirt1 in the
presence of Lipofect n transfection reagent (10 µL/mL) and co-treated w th different concentra io s
of resv ratrol (1, 5, 10 µM) for 21 days in algin t cultures, and cell viability was measured using the
MTT meth d. The results are provided as mean value with standard deviations from at least three
independent experiments. Values w re compared to th control, and statistically-significant values
with p < 0.05 are designated by an asterisk (*); p < 0.01 designated by two asterisks (**); (C) Effects
of Sirt1-ASO on Sirt1 expression in CRC cells in alginate culture. Serum-starve HCT116 cells in
alginate culture were either left untreated or transfected with 0.5 µM sense oligonucleotide (SO) control
or antisense oligonucleotides (ASO) against Sirt1 in the presence of Lipofectin transfection reagent
(10 µL/mL) and co-treated with resveratrol (5 µM) for 21 days. Whole cell lysates were prepared and
analyzed by Western blotting with antibodies against Sirt1. Housekeeping protein β-actin served as a
loading control in all experiments.
3.3. Resveratrol-Induced Suppression in Migration and Invasion of CRC Cells Is Blocked by Knockdown
of Sirt1
Next, we investigated whether downregulation of Sirt1 by mRNA modulates the anti-tumor effects
of resveratrol against CRC migration and invasion in the 3D alginate-based culture microenviron ent,
by evaluating through toluidine blue staining. As shown in Figure 3, treatment of the cells with
resveratrol alone inhibited migration of HCT116 (Figure 3A,B) and SW480 (Figure 3A,C) cells through
the alginate-based matrix in a dose-dependent manner. Interestingly, it was noted that there was no
effect of Sirt1-SO on resveratrol-mediated migration inhibition on CRC cells. However, knockdown of
Sirt1 with ASO blocked resveratrol-inhibited migration effects and significantly increased the number
of migrated cells (Figure 3A–C).

















Furthermore,  transfection with  Sirt1‐ASO,  but  not with  control  Sirt1‐SO  (Figure  4A,B),  inhibited 
resveratrol‐induced suppression of Ki‐67 expression  in both CRC cell  lines, indicating that Sirt1 is 
one of the main targeting proteins by resveratrol during resveratrol‐anti‐proliferative effects in CRC 
cells.  Quantitative  Western  blot  analyses  by  densitometric  evaluation  performed  in  triplicate 
confirmed  the  immunofluorescence results  (Figure 4B). Taken  together,  these results showed  that 
resveratrol alone significantly downregulated the expression of Ki‐67, which is one of the principle 
mechanisms of inhibition of tumor growth and invasion. 
Figure 3. Effects of resveratrol and Sirt1-ASO on the invasion of CRC cells in alginate culture.
(A) Serum-starved HCT116 and SW480 cell lines in alginate culture (1 ˆ 106/mL) w re either left
untreated or treated as described above (Figure 2) and emig ated spheroids valuat d by toluidine
blue s aining after 14 days; (B,C) The spheroid numbers of emigrate HCT116 (B) and SW480
(C) cells through alginate beads was quantified after 14 days in culture. The values given a e the
means ˘ st ndard errors of the mean of three replicates. One of three i dependent experiments is
shown. Values were compared to the control, and statistically-significant values ith p < 0.05 a
designated by an asterisk (*); p < 0.01 by two asterisks (**).
3.4. Specific ASO against Sirt1 Blocked Resveratrol-Induced Inhibition of Ki-67 Expression in CRC Cells
Ki-67 protein is used as a marker for cell proliferation, and it has been shown that resveratrol
inhibits its expression [58]. CRC cells (HCT116 and SW480) either served as controls or were
transfected with 0.5 µM Sirt1-SO or Sirt1-ASO in the presence of Lipofectin for 24 h and co-treated
with resveratrol (5 µM) for an additional 24 h, and surviving colonies were collected. The results from
the immunofluorescence analysis (Figure 4A), as well as the immunoblot assays (Figure 4B) showed
that resveratrol alone significantly downregulated the expression of Ki-67 and nuclear localization.
Furthermore, transfection with Sirt1-ASO, but not with control Sirt1-SO (Figure 4A,B), inhibited
resveratrol-induced suppression of Ki-67 expression in both CRC cell lines, indicating that Sirt1 is one
of the main targeting proteins by resveratrol during resveratrol-anti-proliferative effects in CRC cells.
Quantitative Western blot analyses by densitometric evaluation performed in triplicate confirmed the
immunofluorescence results (Figure 4B). Taken together, these results showed that resveratrol alone
significantly downregulated the expression of Ki-67, which is one of the principle mechanisms of
inhibition of tumor growth and invasion.
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Figure 4. Effects of resveratrol and Sirt1-ASO on Ki-67 in CRC cells in monolayer culture as revealed by
immunofluorescence microscopy. Serum-starved HCT116 (A) and SW480 (A) cell lines in monolayer
culture were either left untreated, or treated with resveratrol alone (5 µM), or transfected with 0.5 µM
sense oligonucleotide (SO) control, or antisense oligonucleotides (ASO) against Sirt1 in the presence
of Lipofectin transfection reagent (10 µL/mL) for 24 h and co-treated with resveratrol (5 µM) for an
additional 24 h and fixated with methanol. For immunolabeling, cells were incubated with primary
antibodies against Ki-67 followed by incubation with rhodamine-coupled secondary antibodies and
counterstaining with DAPI to visualize cell nuclei. Images shown are representative of three different
experiments. Magnification 400ˆ; bar = 30 nm; (B) Effects of Sirt1-ASO on Ki-67 expression in CRC cells
in monolayer culture. Serum-starved HCT116 and SW480 cell lines in monolayer culture were either left
untreated or transfected with 0.5 µM sense oligonucleotide (SO) control or antisense oligonucleotides
(ASO) against Sirt1 in the presence of Lipofectin transfection reagent (10 µL/mL) and co-treated with
resveratrol (5 µM) for 24 h. Whole cell lysates were prepared and analyzed by immunoblotting with
antibodies against Ki-67. Housekeeping protein β-actin served as a loading control in all experiments.
Densitometric evaluation of protein expression as revealed by Western blot analysis was performed
in triplicate. Values were compared to the control and statistically-significant values with p < 0.05.
Significant values are marked with an asterisk (*).
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3.5. Knockdown of Sirt1 with Specific ASO Suppresses Resveratrol-Upregulated Sirt1 Expression in CRC Cells
CRC cell lines (HCT116 and SW480) either served as controls or were treated as described
above (Figure 4). The collected cells were subjected to immunolabeling or immunoblotting with Sirt1
antibody. The immunofluorescence analysis (Figure 5A), as well as the immunoblot analysis (Figure 5B)
revealed that resveratrol alone or with control Sirt1-SO significantly upregulated the expression of Sirt1
protein and nuclear localization (Figure 5A,B). In contrast, transfection with Sirt1-ASO (Figure 5A,B)
significantly inhibited resveratrol-induced upregulation of Sirt1 expression in both CRC cell lines,
indicating that Sirt1 is one of the main target proteins by resveratrol during the resveratrol-anti-tumor
effect in CRC cells. Quantitative Western blot analyses by densitometric evaluation performed in
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Figure 5. Effects of resveratrol and Sirt1-ASO on Sirt1 expression in CRC cells in monolayer culture
as revealed by immunofluorescence microscopy. Serum-starved HCT116 (A) and SW480 (B) cell
lines in monolayer culture were either left untreated or treated as described above (Figure 4).
For immunolabeling, cells wer incubat ith primary antibodies aga nst Sirt1 followed by incubation
with rhodamine-coupled secondary antibodies and counterstaining with DAPI to visualize cell nuclei.
Images shown are representative of three different experiments. Magnification 400ˆ; bar = 30 nm;
(B) Effects of Sirt1-ASO on Sirt1 expression in CRC cells in monolayer culture. Serum-starved HCT116
and SW480 cell lines in monolayer culture were either left untreated or treated as described above
(Figure 4). Whole cell lysates were prepared and analyzed by Western blotting with antibodies against
Sirt1. Housekeeping protein β-actin served as a loading control in all experiments. Densitometric
evaluation of protein expression as revealed by immunoblot analysis was performed in triplicate.
Values were compared to the control and statistically-significant values with p < 0.05. Significant values
are marked with an asterisk (*).
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3.6. Knockdown of Sirt1 with Specific ASO Blocks Resveratrol-Inhibited NF-κB Activation in CRC Cells in the
Alginate Tumor Microenvironment
To investigate the underlying mechanism of the sensitivity of CRC cells to resveratrol, we
examined whether the effects of resveratrol on CRC cells’ growth and metastasis in 3D alginate
cultures was associated with the inhibition of NF-κB activation. Several lines of evidence have
suggested that NF-κB mediates tumor progression, and the tumor chemoresistance of different tumor
cells is known to activate NF-κB expression [59,60]. Our group has shown previously that co-treatment
with resveratrol reduced NF-κB activation in IL-1β, but not in ASO-treated normal cells, indicating
that Sirt1 suppression on mRNA levels is not reversible by resveratrol and highlighting the essential
role of Sirt1 in the resveratrol-specific signaling pathway [61]. CRC cells (HCT116 and SW480) in
alginate culture were either left untreated or transfected with 0.5 µM sense oligonucleotide (SO)
control or antisense oligonucleotide (ASO) against Sirt1 in the presence of Lipofectin and co-treated
with resveratrol (5 µM) for 14 days. Nuclear cell fractions were prepared and analyzed by Western
blotting. Transfection with ASO against Sirt1 induced phosphorylation and translocation of NF-κB
(p50 and p65) to the nucleus (not shown). Co-treatment with resveratrol suppressed NF-κB activation
in Sirt1-SO-treated, but not in Sirt1-ASO-treated cells, indicating that Sirt1 suppression on mRNA
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Figure 6. Effects of resveratrol or/and ASO against Sirt1 on NF-κB signaling pathways in CRC
cells. (A) Antisense oligonucleotide against Sirt1 induced phosphorylation and translocation of
NF-κB in nuclear extracts in CRC cells. Serum-starved HCT116 and SW480 cell lines in alginate
culture (1 ˆ 106/mL) were either left untreated or transfected with 0.5 µM sense oligonucleotide (SO)
control or antisense oligonucleotides (ASO) against Sirt1 in the presence of Lipofectin transfection
reagent (10 µL/mL) and co-treated with resveratrol (5 µM) for 14 days. Nuclear cell fractions were
prepared and examined by Western blot analysis using antibodies against phospho-NF-κB and nuclear
protein poly(ADP-ribose) polymerase as a loading control. Western blots shown are representative
of three independent experiments; (B) Effects of resveratrol and/or ASO against Sirt1 on acetylation
and phosphorylation of NF-κB and Sirt1/NF-κB interaction in CRC cells. After completion of the
experiments, whole cell extracts were immunoprecipitated (IP) with anti-NF-κB antibody or anti-Sirt1
antibody and then analyzed by Western blotting (WB) using antibodies against Sirt1, acetyl-lysine and
phospho-NF-κB. The same immunoprecipitates were then reblotted with NF-κB or Sirt1 antibody.
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3.7. Downregulation of Sirt1 with ASO Blocks Resveratrol-Induced Sirt1 Association, De-Acetylation and
Phosphorylation of NF-κB in CRC Cells
The results of other investigations and our laboratory have shown that stimulation of Sirt1
enzymatic activity by resveratrol correlated with increased de-acetylation of NF-κB, suggesting that
both proteins interact together [33,53]. Therefore, next, we performed co-immunoprecipitation assays
to examine the interaction of Sirt1 and NF-κB in CRC cells in alginate tumor microenvironment
cultures. HCT116 and SW480 cells were either left untreated or treated as described above
(Figure 6A). Whole cell extracts were immunoprecipitated with antibody against NF-κB and
then immunoblotted with anti-Sirt1 antibodies. As shown in Figure 6B, immunoprecipitates
from CRC cells in Sirt1-ASO-/resveratrol-treated cultures revealed strong co-immunoprecipitation
of Sirt-1 protein with the NF-κB protein (Figure 6B). In contrast, in untreated controls and
Sirt1-SO-/resveratrol-treated cultures, marginal Sirt1 co-immunoprecipitation with the NF-κB
protein was observed (Figure 6B). Moreover, the same samples were immunoprecipitated with
anti-Sirt1 and probed by Western blotting with antibodies against p-NF-κB, acetyl-lysine and
Sirt1. Immunoprecipitates from CRC cells in untreated controls and Sirt1-SO/resveratrol-treated
cultures, but not from Sirt1-ASO/resveratrol-treated cultures, revealed inhibition or marginal
co-immunoprecipitation of acetylated and phosphorylated NF-κB subunits (p50/p65) (Figure 6B).
Taken together, these findings indicate that downregulation of Sirt1 with specific ASO knocked down
Sirt1 protein levels and Sirt1-NF-κB complex formation during tumorigenesis in alginate cultures
(Figure 6A,B), and this blocked the ability of resveratrol to deacetylate and phosphorylate NF-κB,
which may, at least in part, inhibit resveratrol-promoting anti-tumorigenic effects in CRC cells.
3.8. Resveratrol-Induced Suppression of NF-κB-Dependent Gene Products Involved in Proliferation and
Metastasis is Blocked by Knockdown of Sirt1 in CRC Cells
It has been reported that NF-κB regulates the expression of genes involved in proliferation,
invasion and metastasis [7]. The alginate cultures of CRC cells were either left untreated or treated
as described above (Figure 6A). As shown in Figure 7, we examined further the expression of the
NF-κB-regulated gene products that are involved in proliferation, invasion (MMP-9) and metastasis
(CXCR4). The results of Western blot analysis showed clearly that Sirt1-SO/resveratrol-treated cultures,
but not Sirt1-ASO/resveratrol-treated cultures, downregulated the expression of the mentioned
proteins in CRC cells. Taken together, these results demonstrate that specific suppression of Sirt1
in CRC cells by Sirt1-ASO, at least in part, is one of the important anti-tumorigenic mechanisms in






















with  increased abundant membrane extensions, microvilli and  long  filopodia  (Figure 8D). Taken 
together,  these  results  indicate  that  the  resveratrol/Sirt1  signaling  pathway  induces  an  MET 
(mesenchymal  to  epithelial  transition)  phenotype  in  CRC  cells  in  the  alginate  tumor 
microenvironment. 
Figure 7. Effects of resveratrol or/and ASO against Sirt1 on NF-κB-regulated gene products involved
in proliferation and metas asis in colorectal cancer cells. Serum-starved HCT116 and SW480 cell lines
in alginate culture (1 ˆ 106/mL) were either left untreated or treated as described above (Figure 6).
Whole cell lysates were fr ctionated a d subject d to stern blotting with antibodies against MMP-9,
CXCR4 and β-actin. Housekeeping protein β-actin served as a loading control in all experiments.
3.9. Resveratrol Induces Epithelial Phenotype (MET) in Colorectal Cancer Cells, but Not in the Presence of
ASO against Sirt1 in 3D Alginate Culture
To examine whether the growth-suppressive effects of resveratrol in CRC colonosphere formation
in 3D alginate cul ure are associated wi h any ultrastr ctural cell morphology ch ng s on the cell-cell
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behavior, transmission electron microscopic evaluations were performed (Figure 8A). After a 14-day
culture period, untreated alginate cultures of HCT116, SW480 (not shown) and cells transfected with
Sirt1-SO (not shown) showed morphological features of viable cell proliferation and aggregation
formation encapsulated in alginate. Cells were mainly round to oval, contained a well-developed
rough endoplasmic reticulum, a large Golgi apparatus and other organelles, such as mitochondria, all
of which indicate the maintenance of metabolic functions (Figure 8A). CRC cells contained numerous
abundant microvilli and cell surface processes (Figure 8A). Opposite to this, in the presence of
resveratrol alone or co-treated with resveratrol and transfected with control Sirt1-SO, a conversion
to an epithelial morphology was observed. CRC cells were observed to grow in close clusters with
almost a planar surface (Figure 8B,C). Furthermore, CRC cells transfected with Sirt1-ASO (not shown)
or co-treated with resveratrol exhibited a mesenchymal-like morphology associated with increased
abundant membrane extensions, microvilli and long filopodia (Figure 8D). Taken together, these results
indicate that the resveratrol/Sirt1 signaling pathway induces an MET (mesenchymal to epithelial
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recurrence,  metastasis  and  morbidity  [1].  Furthermore,  it  has  been  reported  that  tumors  are 
multigenic diseases, and most chemotherapies alone are toxic and ineffective in a large majority of 
patients and will not have much  future. Therefore, new preventive or  therapeutic agents  that are 
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pathway.  It has  been  shown  that  resveratrol  exerts  its positive  effects  by promoting  the protein 
deacetylase  enzyme  silent  information  regulator  2/Sirtuin  1  (Sirt1)  activity  [62,63]  through  an 
Figure 8. Transmission electron microscopic investigation of cell-phenotype behavior in CRC cells in
alginate beads after treatment with resveratrol or/and ASO against Sirt1. Serum-starved HCT116 cells
in algi ate culture (1 ˆ 06/mL) were r left untreated (A), or tr ated with resver trol alone (5 µM)
(B), or transfected with 0.5 µM sense oligonucl e (SO) control (C), or antisense oligonucleotides
(ASO) against Sirt1 (D) in the presence of Lipofectin transfection reagent (10 µL/mL) and co-treated
with resveratrol (5 µM) for 14 days. After 14 days of culture, transmission electron microscopic
observations of HCT116 cells in alginate showed in control cultures tumor cells with a planar surface
and microvilli (*) on their surface (A). Treatment with resveratrol alone or co-treated tumor cells
(HCT116) with resveratrol and control-SO showed only a few microvilli, but they had contact planar
surface (arrows) (B,C). Sirt1-ASO- and resveratrol co-treated tumor cells contained abundant microvilli
on their surface (D). Scale bar = 1 µm.
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4. Discussion
Colorectal cancer is one of the most prevalent malignant tumors in the world, with high rates of
recurrence, metastasis and morbidity [1]. Furthermore, it has been reported that tumors are multigenic
diseases, and most chemotherapies alone are toxic and ineffective in a large majority of patients and
will not have much future. Therefore, new preventive or therapeutic agents that are pharmacologically
safe and effective are urgently needed. Resveratrol as a multi-targeted safe natural polyphenolic
compound [15] has been linked with chemosensitizing potential and anticancer properties; however,
the mechanisms of the complex roles of resveratrol molecular signaling during carcinogenesis are still
poorly understood.
The aim of this paper was to determine the mechanisms by which resveratrol suppresses tumor
cell growth and metastasis in CRC cells by targeting Sirt1 protein and regulating the NF-κB signaling
pathway. It has been shown that resveratrol exerts its positive effects by promoting the protein
deacetylase enzyme silent information regulator 2/Sirtuin 1 (Sirt1) activity [62,63] through an allosteric
mechanism [64] and has emerged as an agent that can extend the life span, probably through the delay
of most chronic illnesses, including cancer [65], by preventing genome instability [66,67].
We showed that resveratrol inhibited the proliferation, invasion and metastasis of CRC cells
(HCT116 and SW480) in 3D-alginate cultures, and this was blocked by knockdown of Sirt1 by using
ASO, suggesting that Sirt1 suppression on mRNA levels is not reversible by resveratrol, highlighting
the crucial role of this enzyme. Furthermore, it has been recently shown that resveratrol suppresses the
proliferation and growth of gastric cancer cells in a Sirt1-dependent manner in vitro and in vivo [68];
however, we have shown in this report for the first time the inhibition of CRC cell proliferation
through the resveratrol/Sirt1 pathway in 3D alginate cultures. Our findings are consistent with
reports that show resveratrol can block the proliferation of diverse cancer cells through modulation of
cell cycle regulatory gene products, induction of apoptosis by upregulation of p53 and inhibition of
anti-apoptotic gene products [20,58,68,69].
Recent reports from our and other laboratories have revealed that alginate culture provides an
excellent tumor microenvironment, and CRC cells encapsulated in 3D alginate cultures proliferated
with detachment of the tumor cells from the alginate and formed metastases, suggesting that this
model is suitable to investigate the initial steps of tumorigenesis, as it is comfortable to perform in vitro
the sequential steps of CRC metastasis mimicking the microenvironment of CRC tumor in vivo [52,70].
We further noticed that the proliferation marker Ki-67 and tumor-promoting factors (MMP9, CXCR4)
were significantly downregulated by resveratrol in CRC cells. These results are consistent with previous
studies, which showed that resveratrol inhibits angiogenesis, proliferation and metastasis in different
kinds of tumors [71–73].
To examine the mechanism of resveratrol signaling, we first investigated whether the NF-κB
transcription factor pathway was involved. We found that downregulation of NF-κB activation and
nuclear translocation by resveratrol, which is constitutively activated in CRC cells, could be a possible
mechanism. Furthermore, we could also show that NF-κB-regulated gene products (CXCR4 and
MMP-9), which are expressed by CRC cells, were also significantly downregulated by resveratrol.
Interestingly, we have further demonstrated that inhibition of NF-κB nuclear translocation and
NF-κB-regulated gene products by resveratrol was reversed through Sirt1 suppression on mRNA
levels, thus suggesting that more than one mechanism may be involved in the anti-tumor and
anti-proliferative activity of resveratrol. Indeed, several lines of evidence suggest that resveratrol has
various chemoregulatory effects in different kinds of cells and signaling pathways in a Sirt1-dependent
mode [68,74,75], as demonstrated by knockdown experiments. We also showed that the negative
effect of resveratrol on CRC cells was, at least in part, regulated by the inhibition of transcription
factor NF-κB acetylation and phosphorylation. Moreover, immunoprecipitation and Western blotting
results clearly showed functional and physical interactions between NF-κB and Sirt1, highlighting
that this interaction may play an important role in regulating resveratrol’s anti-tumor effects in CRC.
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Furthermore, the inhibitory effect of resveratrol on acetylation and phosphorylation of NF-κB was
abolished through knockdown of Sirt1 by mRNA.
It has been shown that resveratrol is one of the most potent Sirt1 activators by provoking
a structural conformational change in Sirt-1, inducing the acetylated substrate and NAD, consequently
resulting in an increased enzymatic activity [33], which has also been associated with apoptosis [76].
Indeed, many Sirt1 substrates are transcription factors and key regulators known to participate in
embryonic growth and in neoplasia (i.e., p53, NF-κB, Ku70 and FoxOs) [77]. In our earlier studies,
we also demonstrated that resveratrol is a potent suppressor of the NF-κB signaling pathway in
different cell types [78–80], which has been closely linked to inflammation and cancer [7] and was found
to promote proliferation and metastasis [15,81]. The physical interaction between NF-κB and Sirt1
indicates that NF-κB could mediate resveratrol/Sirt1-dependent anti-proliferative and anti-metastasis
function in CRC cells, and this was consistent with the finding by knockdown of Sirt1 by using
ASO. Our findings are further in agreement with studies that resveratrol downregulates proliferation,
invasion and metastasis in glioma, lung carcinoma and breast tumors [71–73,82]. Our findings indicate
clearly that Sirt1 serves as a tumor suppressor in CRC cells in alginate culture, and the toxic effect of
resveratrol on the tumor cells appears to be, at least in part, the result of specific resveratrol-caused
activities of a cardinal favorable effect of Sirt1 protein activation.
It has been shown that the anti-aging effects of resveratrol might be mediated via different
mechanisms, like anti-oxidation, anti-cyclooxygenase activity and anti-free radical activity, effects
on cell cycles in vitro and in vivo and through activation of Sirt1, which is a conserved determinant
of life span upon calorie restriction [33,77,83,84]. In contrast, resveratrol has been found to suppress
growth and proliferation in diverse tumor cells by various molecular targeting [85,86]. Indeed, several
lines of evidence have reported that Sirt1 may have controversial complex roles, either as a cancer
suppressor or as a cancer promoter [37,38,41]. It has been considered that phytopharmaceuticals can
modulate different cell-signaling pathways by the regulation of different molecular targets in diverse
cell types. The reciprocal chemomodulatory effects of resveratrol in various cell types may be, at least
partially, due to the bifurcated roles of Sirt1 in tumors (promoting and/or suppressing tumorigenesis),
suggesting an issue of the nature of genes that are integrated in the genome maintenance of cells.
It has been suggested that Sirt1 plays an important role in epigenetic modifications of chromatin
structure and DNA repair by deacetylation [87,88]; thus, Sirt1 controls the cellular response to stress.
The condition and activity of Sirt1 protein in tumor cells may therefore probably play a role to cause
the cell response to epigenetic stress and treatment.
Recently, we have shown that resveratrol, at least in part, suppresses the proliferation and
metastasis of CRC cells by upregulation of intercellular junctions in alginate cultures [51]. The
ultrastructural electron microscopic examinations in this study have shown clearly that CRC cells’
surface revealed in the control contained numerous abundant microvilli and cell surface processes
and showed numerous intercellular junctions on the planar surface. Interestingly, through treatment
with resveratrol or co-treatment with control SO and resveratrol, a dramatic conversion to an epithelial
ultrastructural morphology with numerous intercellular junctions on the planar surface was observed.
In contrast, in the presence of Sirt1-ASO or co-treatment with resveratrol and Sirt1-ASO, the CRC cells
underwent ultrastructural changes with highly metastatic signs, e.g., the development of microvilli
on nearly the entire surface of the cells and microfilaments, indicating that the inhibition effects of
resveratrol on CRC cell migration and proliferation are dependent on Sirt1. According to previous
studies, tight cell-cell contact between tumor cells is associated with more cell integrity and tumor
metastasis suppression [89,90]. These findings are consistent with other studies, which have shown
that cancer cell surface morphological changes are closely involved with malignant behavior and
proliferation of tumors [90,91]. Indeed, it seems that the intercellular adhesion junction may have a
regulatory effect on cell aggregation and stabilization of the tumor cells, leading to malignity and
metastasis originating from cancer cells [90,92,93].
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Evidence from in vivo studies has shown that resveratrol is absorbed after oral administration
and metabolized and conjugated to yield resveratrol glucuronide [94]; its peak concentration was
achieved after 60 min [95] and revealed the good tissue distribution and clearance of resveratrol [58].
Furthermore, it has been reported that a combination therapy of traditional chemotherapy agents with
natural compounds has the potential to target more signaling pathways involved in tumorigenesis and
limits the toxicity effects from chemotherapeutic agents, and several studies have shown the benefit of
this combination therapy in colorectal cancer cells [96,97].
5. Conclusions
In conclusion, we found that resveratrol, by targeting the subcellular Sirt1 signaling pathway, is
one of the main mechanisms of the anti-tumor effects of resveratrol on CRC cells. The bifurcated role
of the resveratrol/Sirt1 signaling pathway with various signaling targets in tumor cellular processes
suggests the therapeutic potential of resveratrol in the prevention/treatment of human CRC.
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